Social media

Obesity trials are evolving, and weight alone is no longer enough. Join our live webinar to explore how the complementary tools of COAs + DHTs can deliver richer patient insights, enhancing obesity clinical trials. 📅 O...

ICON is a proud supporter of National Liver Awareness Month. In the past 5 years, ICON has participated in 124 hepatology studies which include MASH and viral hepatitis indications. We’re committed to bring life-changi...

Clinical development processes for pediatric trials differ from adult trials. Register for our webinar to learn about regulatory strategies and tools in developing pediatric clinic trials and an interactive tool which he...

Identifying the differences between the clinical development processes for pediatric trials and adult trials can be difficult, especially when resources are constrained. Join ICON’s Heather Peterson and Jo Dewhurst for a...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today: https://ow.ly/wzQ950X4eSt C...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today: https://ow.ly/CYC450X4eQq C...

September is #childhoodcancerawareness month. In the past 5 years, we have participated in 421 pediatric clinical studies, including 24 hematologic malignancy and 18 solid tumour studies involving pediatrics patients. Le...

September is #childhoodcancerawareness month. In the past 5 years, we have participated in 421 pediatric clinical studies, including 24 hematologic malignancy and 18 solid tumour studies involving pediatrics patients. Le...

Today marks the start of Biomarkers and Precision Medicine, and the ICON team is ready to connect. Visit Conor Gallagher, Zafar Alam, and our speaker Andrew Roche at booth \#51 to learn how our new Multiplex Immunofluo...

Our comprehensive formulation screening and optimisation process identifies the best exposure levels, enabling data-driven decisions that enhance early phase clinical trial success rates. Experience reduced trial itera...

Our comprehensive formulation screening and optimisation process identifies the best exposure levels, enabling data-driven decisions that enhance early phase clinical trial success rates. Experience reduced trial itera...

ICON is pleased to participate in #CPHIFrankfurt, taking place from 28 to 30 October at Messe Frankfurt. Visit us at booth 6.1F95 to learn how ICON’s Accelerated Pharmaceutical Solutions are helping partners bring therap...